RxDoctor Payments Data

Jennifer Liu-Burdowski, MD

Gastroenterology · Danbury, CTNPI 1952748352

Payments from drug & device makers

What this record shows

This record is dominated by grants: $25,000 of the $26,517 with a category attached, or 94.3%. Boston Scientific accounts for 94.8% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2020 at $25,000 and has fallen 99.1% since, to $232 in 2025.

$26,517in general payments, 2019–2025

Across 31 payments — averaging $855.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$25K
  • Cook Medical LLC$292
  • Medtronic$188
  • Steris Corporation$178
  • Sanofi$171
  • Olympus America Inc.$151
  • plus $404 from 6 others

What the payments were for

  • Grants$25,00094%
  • Food & beverage$1,5176%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,517 in reported general payments places this provider in the 85th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$88,912
Medicare patients
229
Services billed
547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase17$21,786
Omeprazole128$2,975
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates28$1,740
Pantoprazole Sodium59$791
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg37$556
Famotidine29$379

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$30$21,78617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →